
M3GAN 2.0 Is a Horror Sequel With No Horror
Warning: This post contains spoilers for M3GAN 2.0.
M3GAN became a surprise hit in early 2023, earning nearly $182 million worldwide against a budget of just $12 million, due in part to the balance the movie managed to strike between creepy horror and campy comedy. Here was an AI-powered doll who came pre-loaded with meme-worthy dance moves and the ability to spontaneously burst into an a cappella rendition of Sia's "Titanium," but who was also capable of chasing school children into oncoming traffic and fatally wielding a machete. Over two years later, M3GAN 2.0 brings its sassy titular android back for a sequel that delivers on the comedy front, but strips M3GAN of her horror appeal in favor of a more action-centric plot.
When a horror sequel featuring the same big bad as the first movie gets the green light, there's generally one of two routes it can go: a new and improved (or, more often, not so impressive) take on the original story or a Terminator 2-style installment in which the villain comes up against an even greater threat. M3GAN 2.0, written and directed by Gerard Johnstone, opts for the latter, a decision that sends the franchise in a new direction by giving M3GAN (played by Amie Donald and voiced by Jenna Davis) a redemption arc following her previous murderous rampage.
"For me, it was just so obvious, because the reaction to the first film happened on this global scale," Johnstone told Variety of the reason for the tonal shift. "The technology that M3GAN has is being fought over by various nations. At the moment, everyone's in this race to be the first to get AGI. It felt like a story that needed to play out on a much bigger canvas."
In the two years that have passed since the events of the first film, roboticist Gemma (Allison Williams) has become a staunch advocate for government regulation of AI, while her now-preteen niece Cady (Violet McGraw) has thrown herself into computer science and the martial arts practice of aikido to work through her trauma. But when a team of FBI agents breaks into their home one night, Gemma learns that not only did M3GAN's digital consciousness survive the destruction of her body, but her underlying tech was also stolen to create a military-grade AI super-soldier named AMELIA (Ivanna Sakhno). Oh, and AMELIA has gone rogue and wants to destroy humanity.
Naturally, this development forces Gemma to team up with M3GAN and build her a new and improved body in order to try to save the world alongside her colleagues Cole (Brian Jordan Alvarez) and Tess (Jen Van Epps), and fellow tech activist Christian (Aristotle Athari)—a potential love interest who, surprise, actually turns out to be the person behind AMELIA's creation. While we won't get into the somewhat convoluted details of how exactly AMELIA intends to bring her goals to fruition, just know the movie reads as a satirical cautionary tale about the evolution of AI. Johnstone, however, has said he views the sequel as more of a parenting allegory. "We're not saying, 'Don't build AI.' We're asking, 'What happens when you don't train it right?'" he told Creative Screenwriting. "You don't train kids like dogs. You raise them. That's the same with AI."
In the end, an action-packed showdown at a Palo Alto tech campus culminates in M3gan proving she has developed true empathy by sacrificing herself in order to save Cady and Gemma, and eliminate the threat of AMELIA and the mysterious all-powerful Motherboard AI she's after. But worry not, M3GAN 2.0's final moments reveal M3GAN's source code is still alive and well, leaving the door open for future sequels that could fall under a variety of genres.
According to Johnstone, the sky is apparently the limit. "I would not be surprised if there's another five of these movies," he told the Hollywood Reporter. "So, who knows, maybe I'll come back for the fifth one."

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
17 minutes ago
- Business Upturn
Reacher Season 4: Release date rumors, cast updates and what to expect next
By Aman Shukla Published on June 28, 2025, 18:00 IST Last updated June 28, 2025, 11:16 IST Reacher fans, buckle up! The action-packed Prime Video series, led by Alan Ritchson's unstoppable Jack Reacher, has everyone hyped for Season 4 after that jaw-dropping Season 3 finale. With no official word on a premiere date yet, whispers about the cast, and a juicy new story on the horizon, there's plenty to unpack. Here's the latest scoop on Reacher Season 4—release date rumors, who's in the lineup, and what kind of chaos Reacher's diving into this time. When's Reacher Season 4 Hitting Screens? No confirmed release date has dropped, which is honestly a bit maddening for fans dying to see Reacher back in action. But here's what's known: Prime Video renewed the show in October 2024, before Season 3 even premiered on February 20, 2025. Filming kicked off in Philadelphia in June 2025, and production's rolling along as of now. Past seasons give a rough idea of the timeline. Reacher usually takes 12 to 15 months from the start of filming to premiere. The gap between Season 1 and Season 2 stretched to 22 months because of industry strikes, but Season 3 closed the gap to about 14 months. So, expect Season 4 to land sometime between April and October 2026. Some online chatter points to a late 2026 or early 2027 debut, especially if the Neagley spin-off (more on that later) shakes up the schedule. For now, mid-2026 feels like a solid guess. Stay patient, folks—it'll be worth it! Reacher Season 4 Expected Cast Reacher loves switching things up, with Jack wandering into new towns and meeting fresh faces each season. That means a mostly new cast every time, though a couple of favorites tend to stick around. Here's the rundown on who's returning and who's joining the fray. Returning Stars Alan Ritchson as Jack Reacher : The man himself, Ritchson's back as the towering, sharp-minded drifter who solves problems with brains and brawn. He's teased Season 4 as possibly the 'best yet,' and that's got fans buzzing. Maria Sten as Frances Neagley (probably): Neagley, Reacher's tough-as-hell Army pal, has shown up in every season so far. Nothing's set in stone for Season 4, but with her own spin-off in the works, a cameo or bigger role seems likely. Fresh Faces for Season 4 The new season's packing a stacked cast, per reports from Variety and Deadline in June 2025. Check out who's joining: Jay Baruchel as Jacob Merrick : A cop crossing paths with Reacher in whatever mess unfolds. Sydelle Noel as Tamara Green : A detective who'll likely be deep in the season's mystery. Agnez Mo as Lila Hoth : A young Indonesian woman hunting for her American father in Philly—sounds like a big plot driver. Anggun : Details on her role are hush-hush, but expect something intriguing. Kevin Corrigan as Detective Docherty : Tamara's partner, probably digging into the same case. Kevin Weisman as Russell Plum : A journalist poking around for a story, bound to stir up trouble. Marc Blucas as John Samson : A Congressman tangled in some shady dealings. Kathleen Robertson as Elsbeth Samson: John's wife, likely tied to the political intrigue. This lineup hints at a wild, twisty story mixing cops, politicians, and personal quests. Since Reacher tends to wrap up supporting characters' arcs each season, don't expect Season 3 folks like Anthony Michael Hall's Zachary Beck or Brian Tee's Quinn to return—their stories ended with a bang. That said, Sonya Cassidy's Susan Duffy from Season 3 might sneak in for a cameo, given her spark with Reacher. What to Expect in Reacher Season 4 Here's where things get spicy. Season 4's adapting Gone Tomorrow , the 13th book in Lee Child's Reacher series. A teaser on the show's Instagram showed a Season 4 script on a New York City subway seat, tying directly to the book's opening. The official logline sets it up like this: 'New York City. Two in the morning. A subway car heading uptown. Jack Reacher, plus five other passengers. Four are okay. The fifth isn't. And if you think Reacher isn't going to get involved . . . then you don't know Jack.' Talk about a hook! In Gone Tomorrow , Reacher's on a late-night subway ride when he spots a woman, Susan Mark, acting like a potential suicide bomber. When he approaches, she takes her own life, kicking off a crazy chain of events. Soon, he's neck-deep in a conspiracy stretching from New York to D.C., California, and even Afghanistan, facing off against some seriously dangerous players. The logline mentions 'ruthless foes from the highest echelons of power,' so expect a high-stakes game of cat and mouse. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
30 minutes ago
- Yahoo
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
The healthcare sector offers an abundance of high-growth investment opportunities. Companies leveraging artificial intelligence and genomic medicine are delivering innovative therapies with significant potential. Small-cap and under-the-radar stocks with strong growth possibilities merit closer investor attention. 10 stocks we like better than TransMedics Group › There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving. Investors stand to benefit as healthcare leaders and emerging players address the needs of an aging global population and the rising prevalence of chronic diseases. Here are 10 under-the-radar healthcare stocks that could be great buys for your portfolio. Certara (NASDAQ: CERT) is poised to capitalize on the transformation in medicine driven by artificial intelligence (AI), providing bio-simulation software and services that accelerate drug development. The company plays a crucial role in the pharmaceutical industry. Over 90% of all novel drugs approved by the Food and Drug Administration (FDA) since 2014 have leveraged its technology. Its AI-driven solutions enhance research and development (R&D), enabling faster and more precise drug development. Certara deserves a closer look by investors seeking to tap into the AI-driven healthcare transformation. Beam Therapeutics (NASDAQ: BEAM) is a clinical-stage biotech pioneering precision-based gene editing therapies for genetic diseases, including sickle cell disease. Its innovative technology enables precise single-nucleotide DNA changes, potentially offering a safer alternative to traditional CRISPR genetic engineering. Beam has reported early success in gene correction, with its lead candidate, BEAM-101, in phase 1/2 trials for sickle cell disease. While the company still has a lot to prove, its differentiated approach and clinical progress position it for remarkable growth in the long term. Inspire Medical Systems (NYSE: INSP) develops implantable neurostimulation devices for obstructive sleep apnea, offering its FDA-approved Inspire therapy as a noninvasive alternative to CPAP machines. In its first quarter (the period ended March 31), revenue surged 23% year over year to $201 million, driven by growing U.S. adoption and new international approvals. With increasing demand for sleep apnea treatment, Inspire has a significant opportunity to capture market share. Insulet (NASDAQ: PODD) specializes in tubeless insulin pump technology. Its Omnipod system simplifies diabetes management for Type 1 and insulin-dependent Type 2 patients globally, offering convenience and improved outcomes. With a 2025 revenue growth target of 19% to 22%, the company is poised for continued expansion, particularly in underpenetrated international markets. Insulet's strong growth trajectory positions it to reward shareholders further. Krystal Biotech (NASDAQ: KRYS) focuses on rare skin diseases. Its FDA-approved gene therapy, Vyjuvek, for dystrophic epidermolysis bullosa (fragile skin that blisters easily) is expected to approach $400 million in revenue this year, solidifying its position as a best-in-class treatment. Vyjuvek's success validates Krystal's R&D, bolstering confidence in its pipeline and unlocking added market potential. LifeMD (NASDAQ: LFMD) operates a telehealth platform providing specialized virtual care in weight loss, men's health, and dermatology. A partnership with Novo Nordisk to offer Wegovy, a leading GLP-1 treatment, has driven impressive growth, with first-quarter revenue surging 49% year over year for the period ended March 31. LifeMD could expand its growing user base into a comprehensive health management ecosystem to fuel growth and solidify its telehealth leadership. Option Care Health (NASDAQ: OPCH) is the leading U.S. provider of home and alternative-site infusion services, delivering crucial therapies for chronic and acute conditions like cancer, immune deficiencies, and infections. As the healthcare industry shifts toward more personalized and cost-effective care, Option Care Health is in position to capitalize on the strong demand, with its extensive network and high-quality services. Tempus AI (NASDAQ: TEM) harnesses artificial intelligence to advance precision medicine, using its collection of clinical and molecular data from more than 40 million patients to power diagnostics in oncology, cardiology, and beyond. The company projects its revenue to climb by more than 80% this year, to about $1.3 billion. Tempus AI's scalable platform and extensive data ecosystem present substantial opportunities for expansion and impact in personalized healthcare. TransMedics Group (NASDAQ: TMDX) has revolutionized organ transplantation with its Organ Care System (OCS), the only FDA-approved device for heart, lung, and liver transplants that extends organ preservation time. The company's projected revenue growth of 30% this year underscores the strong momentum in a global expansion opportunity. Veeva Systems (NYSE: VEEV) offers cloud-based software that streamlines clinical, regulatory, and commercial processes for life sciences companies. Serving over 1,000 customers, including major pharmaceutical companies and emerging biotechs, Veeva's platform is well positioned to capitalize on the industry's increasing reliance on digital solutions for innovation and compliance. Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Dan Victor has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Beam Therapeutics, Inspire Medical Systems, TransMedics Group, and Veeva Systems. The Motley Fool recommends Insulet, Krystal Biotech, and Novo Nordisk. The Motley Fool has a disclosure policy. 10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential was originally published by The Motley Fool


USA Today
an hour ago
- USA Today
Spoilers! Why 'M3GAN 2.0' is actually a 'redemption story'
Spoiler alert! We're discussing major details about the ending of 'M3GAN 2.0' (in theaters now), so beware if you haven't seen it yet. 'You wouldn't give your child cocaine. Why would you give them a smartphone?' That's the sardonic hypothetical posed by roboticist Gemma (Allison Williams) at the start of 'M3GAN 2.0,' a high-octane sequel to the 2023 hit horror comedy. When the new movie picks up, Gemma is tirelessly advocating for government oversight of artificial intelligence, after creating a bratty, pussy-bowed animatronic named M3GAN that killed four people and a dog in the original film. 'Honestly, Gemma has a point,' jokes Williams, the mother of a 3-year-old, Arlo, with actor Alexander Dreymon. 'Any time my son looks at my screen, I'm like, 'This does feel like the way people react to cocaine. This is not going to be easy to remove from his presence.' ' The first movie was an allegory about parenting and how technology is compromising the emotional human bonds that we share with one another. But in the action-packed follow-up, writer/director Gerard Johnstone wanted to explore the real-life ramifications of having M3GAN-like technology unleashed on the world. 'With the way AI was changing, and the conversation around AI was evolving, it opened up a door narratively to where we could go in the sequel,' Johnstone says. How does 'M3GAN 2.0' end? 'M3GAN 2.0' introduces a new villain in Amelia (Ivanna Sakhno), a weapons-grade automaton built by the U.S. military using M3GAN's stolen programming. But when Amelia goes rogue on a lethal mission for AI to rule the world, Gemma comes to realize that M3GAN is the only one who can stop her. Gemma reluctantly agrees to rebuild her impudent robot in a new body, and the sequel ends with an explosive showdown between Amelia and M3GAN, who nearly dies in a noble attempt to save Gemma and her niece, Cady (Violet McGraw). 'If Amelia walked out of that intact, that's a very different world we're all living in. M3GAN literally saves the world,' Williams says. 'When the first movie ends, you're like, 'Oh, she's a bad seed and I'm glad she's gone.' But by the end of this movie, you have completely different feelings about her. There's a feeling of relief when you realize she's still here, which is indicative of how much ground gets covered in this movie.' M3GAN's willingness to sacrifice herself shows real growth from the deadpanning android that audiences fell in love with two years ago. But Johnstone has always felt 'a strong empathy' towards M3GAN and never wanted to make her an outright villain. Even in the first film, 'everything she does is a result of her programming,' Johnstone says. 'As soon as she does something that Gemma disagrees with, Gemma tries to turn her off, erase her, reprogram her, and effectively kill her. So from that point of view, M3GAN does feel rightly short-changed.' M3GAN's desire to prove herself, and take the moral high ground, is 'what this movie was really about,' Johnstone adds. 'I love redemption stories.' Does 'M3GAN 2.0' set up a third movie? For Williams, part of the appeal of a sequel was getting to play with how M3GAN exists in the world, after her doll exterior was destroyed in the first movie. M3GAN is offscreen for much of this film, with only her voice inhabiting everything from a sports car to a cutesy smart home assistant. 'She's just iterating constantly, which tore through a persona that we've come to know and love,' Williams says. 'It's an extremely cool exercise in a movie like this, where we get to end the movie with a much deeper understanding of who this character is. We've now interacted with her in so many different forms, and yet we still feel the consistency of who she 'is.' That's really the fun of it.' In a way, 'she's like this digital poltergeist that's haunting them from another dimension,' Johnstone adds. 'It was a way to remind people she's more than a doll in a dress – she's an entity.' In the final scene of 'M3GAN 2.0,' we see the character living inside Gemma's computer, in a nostalgic nod to the Microsoft Word paper clip helper. (As millennials, 'our relationship with Clippy was very codependent and very complicated,' Williams quips.) But if there is a third 'M3GAN' movie, it's unlikely that you'll see her trapped in that virtual realm forever. 'M3GAN always needs to maintain a physical form,' Johnstone says. 'One aspect of AI philosophy that we address in this film is this idea of embodiment: If AI is ever going to achieve true consciousness, it has to have a physical form so it can feel anchored. So that's certainly M3GAN's point of view at the beginning of the movie: She feels that if she stays in this formless form for too long, she's going to fragment. 'M3GAN always has to be in a physical body that she recognizes – it's another reason why she won't change her face, even if it draws attention to herself. It's like, 'This is who I am and I'm not changing.' '